← boardnext 2026-09
WVE
Wave Life Sciences USA, Inc.distress 1/10 · well-funded / low risk$5.68-1%today-73% from 52w high
Rare / Genetic 1
Lead: obesity · est. market ~$15B (approx, global)
Revenue
$38M
Liquidity
$570M
Runway
3.1 yrs
Shares 1y
+21%
Price & events
-58.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
+0.3%
1W
-5.9%
1M
-22.2%
3M
-57.8%
6M
-33.6%
1Y
-9.3%
2Y
-2.7%
5Y
-31.4%
All
Overview
- Market Cap
- $1.09B
- Volume
- 92.55K
- 52 Week Range
- $5.66 – $21.31
- Total Shares
- 192.38M
- Float Shares
- 90.11M
- Short %
- 13.48%
- % Held by Insiders
- 15.88%
- % Held by Institutions
- 82.82%
- RVOL
- 0.03x
- Beta
- -1.29
Pipeline stages · 1 programs
WVE-N531
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 1/2 | WVE-006 | Alpha-1 Antitrypsin Deficiency | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | WVE-007 | Overweight and Obesity | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-04-15 | Phase 2 | WVE-N531 | Duchenne Muscular Dystrophy | — | enrolling by invitation |
| 2026-06-27 | Phase 1/2 | WVE-N531 | Duchenne Muscular Dystrophy | 26 | recruiting |
| 2025-02-13 | Phase 1 | WVE-006 | Alpha-1 Antitrypsin Deficiency (AATD) | 47 | completed |
Catalyst news & presentations · 19
- 2026Guided 40%trial initiationsecondaryWVE-007 · Initiate clinical trials as incretin add-on and post-incretin maintenanceSEC 8-K
- 2026Guided 40%readoutPhase 1WVE-007 · Additional data from INLIGHT Phase 1 SAD 600 mg cohort.SEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)WVE-008 · CTA submissionSEC 8-K
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026regulatory submissionFiled (NDA/BLA)WVE-006 · FDA feedback on potential accelerated approval pathwaySEC 8-K
- mid-2026readoutWVE-006 · Regulatory feedback from FDA on potential accelerated approval pathwaySEC 8-K
- second quarter of 2026trial initiationsecondaryPhase 2WVE-007 · Initiate Phase 2a multidose portion of INLIGHT in individuals with BMI 35-50 kg/m²SEC 8-K
- mid-2026regulatory submissionFiled (NDA/BLA)WVE-006 · Regulatory feedback on potential accelerated approval pathway.SEC 8-K
- 1Q 2026readoutWVE-007 · six-month follow-up data from Cohort 2 and three-month follow-up data from Cohort 3SEC 8-K
- 2026-02-02partnershipWVE-006 · Wave regains full rights to WVE-006 from GSK.SEC 8-K
- Tomorrow, January 13, 2026conferencedata presentationsecondaryPresentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- fall of 2025readoutPhase 1/2WVE-006 · Data from complete 400 mg single dose cohort in RestorAATion-2SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)WVE-003 · IND submission for potentially registrational Phase 2/3 study with caudate atrophy as primary endpointSEC 8-K
- 3Q 2025readoutPhase 1/2WVE-006 · Data from complete 200 mg multidose and single dose cohorts in RestorAATion-2SEC 8-K
- next weekconferencedata presentationsecondaryWVE-007 · Preclinical data presentations at ECO and ASGCTSEC 8-K
- 1Q 2025readoutPhase 2WVE-N531 · Complete 48-week FORWARD-53 dataSEC 8-K
- first quarter of next yeartrial initiationsecondaryPhase 1WVE-007 · Initiate first-in-human study for WVE-007 in obesitySEC 8-K
- Fall 2024conferencedata presentationsecondaryWVE-007 · Present preclinical data for WVE-007 and other pipeline programs at R&D DaySEC 8-K
- 3Q 2024readoutWVE-N531 · Topline dystrophin data from FORWARD-53 trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $22 (+286% upside) · 16 analysts
- 2026-05-20Wells FargoOverweight
- 2026-05-19HC Wainwright & Co.Buy
- 2026-05-04CitigroupBuy
- 2026-04-30Canaccord GenuityBuy
- 2026-04-29Truist SecuritiesBuy
- 2026-04-14HC Wainwright & Co.Buy
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-23Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 - The Manila Times
- 2026-07-23Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 - GlobeNewswire
- 2026-07-22Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance Singapore
- 2026-07-21Wave Life Sciences Ltd. (WVE) Stock Analysis: Unveiling a Potential 282.85% Upside in Biotech - DirectorsTalk Interviews
- 2026-07-20WAVE LIFE SCIENCES LTD (WVE) Stock Chart - ChartMill
- 2026-07-19Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-17Road Trippin'...More Jakeman Run Fun , Richwood, WVE - WCHS
- 2026-07-14What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.